Zeitschrift für Multiple Sklerose

Kurzer Kommentar

Ups and Downs in MS Therapeutics

Abdul Aftab, and Pankaj Majlumdar

Kurzer Kommentar

Ups and Downs in MS Therapeutics

Abdul Aftab, and Pankaj Majlumdar

Kurzer Kommentar

Ups and Downs in MS Therapeutics

Abdul Aftab, and Pankaj Majlumdar

Kurzer Kommentar

Ups and Downs in MS Therapeutics

Abdul Aftab, and Pankaj Majlumdar

Kurzer Kommentar

Ups and Downs in MS Therapeutics

Abdul Aftab, and Pankaj Majlumdar

Perspektive

Unlocking the Pivotal Role of Ocrelizumab in Transforming Multiple Sclerosis Treatment

Martin Baum, Richard Glenn

Perspektive

Unlocking the Pivotal Role of Ocrelizumab in Transforming Multiple Sclerosis Treatment

Martin Baum, Richard Glenn

Kleiner Rückblick

Unveiling the Burden: Rates and Predictors of Short-Term Disability Claims among Migraine Patients in the US

David Reeds, Sarah Frowler

Kleiner Rückblick

Unveiling the Burden: Rates and Predictors of Short-Term Disability Claims among Migraine Patients in the US

David Reeds, Sarah Frowler

Perspektive

Unlocking the Pivotal Role of Ocrelizumab in Transforming Multiple Sclerosis Treatment

Martin Baum, Richard Glenn

Perspektive

Unlocking the Pivotal Role of Ocrelizumab in Transforming Multiple Sclerosis Treatment

Martin Baum, Richard Glenn

Kleiner Rückblick

Unveiling the Burden: Rates and Predictors of Short-Term Disability Claims among Migraine Patients in the US

David Reeds, Sarah Frowler

Perspektive

Unlocking the Pivotal Role of Ocrelizumab in Transforming Multiple Sclerosis Treatment

Martin Baum, Richard Glenn

Kleiner Rückblick

Unveiling the Burden: Rates and Predictors of Short-Term Disability Claims among Migraine Patients in the US

David Reeds, Sarah Frowler

Kleiner Rückblick

Unveiling the Burden: Rates and Predictors of Short-Term Disability Claims among Migraine Patients in the US

David Reeds, Sarah Frowler

Perspektive

Unlocking the Long-Term Value Proposition: A Comprehensive Analysis of the Cost-Effectiveness of Glatiramer Acetate in the Treatment Landscape of Relapsing-Remitting Multiple Sclerosis from the UK NHS Perspective

Elche Greeds, Oman Godsy

Perspektive

Unlocking the Long-Term Value Proposition: A Comprehensive Analysis of the Cost-Effectiveness of Glatiramer Acetate in the Treatment Landscape of Relapsing-Remitting Multiple Sclerosis from the UK NHS Perspective

Elche Greeds, Oman Godsy

Perspektive

Unlocking the Long-Term Value Proposition: A Comprehensive Analysis of the Cost-Effectiveness of Glatiramer Acetate in the Treatment Landscape of Relapsing-Remitting Multiple Sclerosis from the UK NHS Perspective

Elche Greeds, Oman Godsy

Perspektive

Unlocking the Long-Term Value Proposition: A Comprehensive Analysis of the Cost-Effectiveness of Glatiramer Acetate in the Treatment Landscape of Relapsing-Remitting Multiple Sclerosis from the UK NHS Perspective

Elche Greeds, Oman Godsy

Perspektive

Unlocking the Long-Term Value Proposition: A Comprehensive Analysis of the Cost-Effectiveness of Glatiramer Acetate in the Treatment Landscape of Relapsing-Remitting Multiple Sclerosis from the UK NHS Perspective

Elche Greeds, Oman Godsy

Forschungsartikel

A Comprehensive Review of the Long-Term Effectiveness and Safety of Ocrelizumab as a Disease-Modifying Therapy for Multiple Sclerosis

Johnny Michael Sakr

Forschungsartikel

A Comprehensive Review of the Long-Term Effectiveness and Safety of Ocrelizumab as a Disease-Modifying Therapy for Multiple Sclerosis

Johnny Michael Sakr

Forschungsartikel

A Comprehensive Review of the Long-Term Effectiveness and Safety of Ocrelizumab as a Disease-Modifying Therapy for Multiple Sclerosis

Johnny Michael Sakr

Forschungsartikel

A Comprehensive Review of the Long-Term Effectiveness and Safety of Ocrelizumab as a Disease-Modifying Therapy for Multiple Sclerosis

Johnny Michael Sakr

Volumen 11, Ausgabe 1 (2024)

Ups and Downs in MS Therapeutics

Ups and Downs in MS Therapeutics

Ups and Downs in MS Therapeutics

Ups and Downs in MS Therapeutics

Ups and Downs in MS Therapeutics

Unlocking the Pivotal Role of Ocrelizumab in Transforming Multiple Sclerosis Treatment

Unlocking the Pivotal Role of Ocrelizumab in Transforming Multiple Sclerosis Treatment

Unveiling the Burden: Rates and Predictors of Short-Term Disability Claims among Migraine Patients in the US

Unveiling the Burden: Rates and Predictors of Short-Term Disability Claims among Migraine Patients in the US

Unlocking the Pivotal Role of Ocrelizumab in Transforming Multiple Sclerosis Treatment

Unlocking the Pivotal Role of Ocrelizumab in Transforming Multiple Sclerosis Treatment

Unveiling the Burden: Rates and Predictors of Short-Term Disability Claims among Migraine Patients in the US

Unlocking the Pivotal Role of Ocrelizumab in Transforming Multiple Sclerosis Treatment

Unveiling the Burden: Rates and Predictors of Short-Term Disability Claims among Migraine Patients in the US

Unveiling the Burden: Rates and Predictors of Short-Term Disability Claims among Migraine Patients in the US

Unlocking the Long-Term Value Proposition: A Comprehensive Analysis of the Cost-Effectiveness of Glatiramer Acetate in the Treatment Landscape of Relapsing-Remitting Multiple Sclerosis from the UK NHS Perspective

Unlocking the Long-Term Value Proposition: A Comprehensive Analysis of the Cost-Effectiveness of Glatiramer Acetate in the Treatment Landscape of Relapsing-Remitting Multiple Sclerosis from the UK NHS Perspective

Unlocking the Long-Term Value Proposition: A Comprehensive Analysis of the Cost-Effectiveness of Glatiramer Acetate in the Treatment Landscape of Relapsing-Remitting Multiple Sclerosis from the UK NHS Perspective

Unlocking the Long-Term Value Proposition: A Comprehensive Analysis of the Cost-Effectiveness of Glatiramer Acetate in the Treatment Landscape of Relapsing-Remitting Multiple Sclerosis from the UK NHS Perspective

Unlocking the Long-Term Value Proposition: A Comprehensive Analysis of the Cost-Effectiveness of Glatiramer Acetate in the Treatment Landscape of Relapsing-Remitting Multiple Sclerosis from the UK NHS Perspective

A Comprehensive Review of the Long-Term Effectiveness and Safety of Ocrelizumab as a Disease-Modifying Therapy for Multiple Sclerosis

A Comprehensive Review of the Long-Term Effectiveness and Safety of Ocrelizumab as a Disease-Modifying Therapy for Multiple Sclerosis

A Comprehensive Review of the Long-Term Effectiveness and Safety of Ocrelizumab as a Disease-Modifying Therapy for Multiple Sclerosis

A Comprehensive Review of the Long-Term Effectiveness and Safety of Ocrelizumab as a Disease-Modifying Therapy for Multiple Sclerosis

Zeitschriften-Highlights

Indiziert in